山河药辅(300452) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥191,403,805.41, representing a 10.99% increase compared to ¥172,457,902.67 in the same period last year[4] - Net profit attributable to shareholders was ¥33,838,831.74, an increase of 8.76% from ¥31,114,589.36 year-on-year[4] - The total operating revenue for the first quarter of 2022 was CNY 191,403,805.41, representing an increase of 10.9% compared to CNY 172,457,902.67 in the same period last year[21] - The net profit for the first quarter was CNY 33,506,761.62, an increase of 8.5% from CNY 30,746,016.54 in the previous year[22] - The earnings per share (EPS) for the first quarter was CNY 0.19, compared to CNY 0.17 in the same period last year, reflecting a growth of 11.8%[22] Cash Flow - The net cash flow from operating activities reached ¥4,881,325.98, showing a significant increase of 57.01% compared to ¥3,109,006.22 in the previous year[4] - The net cash flow from operating activities for the current period is $4,881,325.98, an increase of 57.1% compared to $3,109,006.22 in the previous period[25] - Cash inflow from operating activities totaled $143,339,114.30, up 12.9% from $126,903,305.46 in the previous period[25] - Cash outflow from operating activities increased to $138,457,788.32, compared to $123,794,299.24 in the previous period, reflecting a rise of 11.8%[25] - Cash flow from financing activities resulted in a net outflow of $77,997.19, an improvement from a net outflow of $346,497.96 in the previous period[26] Investment and Assets - Research and development expenses for the period amounted to ¥896.14 million, reflecting a 49.92% increase year-on-year, indicating a rise in R&D investment[8] - The company reported a 199.54% increase in investment income, totaling ¥298.48 million, attributed to higher returns from financial products[8] - The total assets at the end of the reporting period were ¥1,004,309,113.55, up 4.33% from ¥962,583,989.34 at the end of the previous year[4] - The total assets increased to CNY 1,004,309,113.55, up from CNY 962,583,989.34, indicating a growth of 4.4%[18] - The total liabilities rose to CNY 264,816,442.66, compared to CNY 256,665,812.73, marking an increase of 3.9%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,289[11] - The largest shareholder, Yin Zhenglong, holds 26.89% of shares, totaling 48,505,734 shares[11] - The total number of restricted shares held by Yin Zhenglong remains at 36,379,300 due to executive lock-up and incentive restrictions[13] - The company has a total of 39,265,101 restricted shares, with 1,947,343 shares released during the period[14] - The top ten shareholders include Shanghai Fosun Pharmaceutical Industry Development Co., holding 11.19% of shares[11] Other Financial Metrics - The company's basic earnings per share increased to ¥0.19, up 11.76% from ¥0.17 in the same period last year[4] - Accounts receivable increased by 85.55% to ¥107,045,000, primarily due to increased sales[7] - Inventory decreased to ¥73,417,708.26 from ¥77,770,805.72, a decline of 5.8%[16] - The company reported a total of 21,377,387.98 in accounts receivable financing, down from ¥36,701,435.94[16] - The company's cash and cash equivalents at the end of the period amount to ¥159,009,263.05, an increase from ¥141,263,215.31 at the beginning of the year[16] Strategic Outlook - The company has not disclosed any new strategies or future outlook in the provided documents[12]